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Abstract
Background Here, the treatment methods and results of patients with phyllodes tumor of the breast (PT) with
distant metastases at a single institution are presented.
Methods A retrospective analysis was performed on a group of 295 patients with PT treated from 1952 to 2010.
Results Distant metastases developed in 37 (12.5 %) patients; 3/160 (1.9 %) patients had benign PT, 6/36 (16.7 %)
were considered borderline, and 28/99 (28.3 %) had malignant PT. Most frequently, the metastases were located in
the lungs; 28 (75.7 %), bone 7 (18.9 %), brain 4 (10.8 %), and liver 2 (5.4 %). Metastases occurred on overage
21 months (2–57) after surgery. Patients with lung metastases were generally treated with monochemotherapy or
polychemotherapy. In one patient Testosterone and in two patients resection of metastases combined with Dox-
orubicin were used. Patients with bones or brain metastases were treated with palliative radiotherapy only or
combined with Doxorubicin. The mean survival (MS) from diagnosis of distant metastases (DM) was 7 months
(2–17). The longest mean survival in patients with bones metastases was 11.8 months, the worst survival was for
patients with brain metastases—2.8 months. Hormone therapy appeared to have low efficacy (MS: 2 months) as well
as monochemotherapy (MS: 3–5 months). Improved MS was obtained using Doxorubicin (7 months) and Doxoru-
bicin with Cisplatin, Cyclophosphamide, or Ifosfamide (9 months).
Conclusion The prognosis of patients with DM from PT is poor. The role of surgery and irradiation of such patients
is very limited. There appears to be no role for the use of hormone therapy. This study showed that polychemotherapy
with Doxorubicin and Ifosfamide suggest that it might be more effective than once thought.
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Introduction
Phyllodes tumor (PT) is a rare fibro-epithelial neoplasm of
the breast that accounts for 0.2–2 % of breast tumors in
women [1–9]. PT is classified as benign or malignant;
however, distinguishing those histotypes is difficult and
based on semi-quantitative evaluation of the stromal
component criteria including nuclear pleomorphism,
mitotic rate, overgrowth, cellularity, and aspects of tumor
margins [1, 2, 4, 7, 10].
The main cause of treatment failure in patients with PT
of the breast is the dissemination of the neoplasm, which is
diagnosed in 1–15 % of all patients [2, 11, 12]. The clinical
behavior of a PT is unpredictable. Distant metastases (DM)
occur mainly in malignant and borderline PT; however,
metastatic spread in the benign type of PT has been
described [11, 12]. The incidence of metastatic disease
among patients with malignant PT is estimated to be
approximately 20–25 % [2, 3].
A metastatic PT carries a poor prognosis with an aver-
age survival time of less than 2 years [2, 12–14]. The
treatment of DM in patients with PT is a matter of debate.
The role of surgery and radiotherapy is limited, and there is
no role for the use of hormone therapy [2, 6, 8, 15]. Che-
motherapy has been used for many years; however, it is
difficult to assess the real value of this treatment due to the
small size of the study groups and the diversity of drugs
used for treatment, as well as the doses and regimens
applied [2, 6, 9, 15–18].
The aim of this study was to present the methods used
and clinical outcomes of patients with DM from PT after
treatment at a single institution in Poland.
Materials and methods
Between January 1952 and February 2010, 295 women
with PT of the breast were treated surgically at the Maria
Skłodowska-Curie Memorial Institute of Oncology, Cancer
Center in Cracow, Poland. All clinical characteristics,
treatment options, and therapy outcomes were acquired by
the review of patients’ charts. The diagnosis and specific
microscopic type of neoplasm were confirmed according to
the WHO classification. All histology slides were re-ex-
amined, and the diagnosis of histotypes of PT was based on
World Health Organization criteria.
The five-year survival with no evidence of disease
(NED) was used as the endpoint for the analysis. 5-year
NED was chosen as the primary endpoint because it
reflects distant tumor control better compared to other
commonly used outcome measures. All patients were fol-
lowed up for at least 5 years (or until death). The mean
follow-up time was 11 years. The log-rank test was used
for evaluation of significance. The level of statistical sig-
nificance was set at p B 0.05. A multivariate Cox propor-
tional hazard model was applied to analyze influence of
evaluated factors on the adjusted survival.
Results
Among all 295 patients, 256 (86.8 %) survived the 5-year
NED. Table 1 shows the clinical outcomes according to the
PT histotypes.
The 5-year NED survival was observed in 96.9 %
patients with benign PT, 83.3 % with borderline PT, and
71.7 % with malignant PT. Two patients in the group with
benign PT died due to other reasons (myocardial infarct
and cerebral hemorrhage). All other patients (3 benign, 6
borderline, and 28 malignant PT) who died during the
5-year follow-up developed DM.
Among 196 patients with benign and borderline PT, 9
(4.6 %) and among 99 patients with malignant PT, 28
(28.3 %) developed DM. The difference was statistically
significant (log-rank test, p\ 0.01).
This study focused on a group of 37 patients with distant
metastases (DM) from PT. The median age of those
patients was 54 (range 48–76 years of age). The tumor
size, defined as the maximal dimension of the tumor, as
reported in the pathology report, ranged from 4 to 8 cm
(mean 6 cm, median 5.5 cm). The tumor measurements
were as follows:\5 cm in 21 (56.8 %) patients, 5–7 cm in
13 (35.1 %) patients, and over 7 cm in 3 (8.1 %) patients.
In two patients, regional lymph node metastases were also
diagnosed. Table 2 shows the localization of DM.
In the group studied, the most frequent metastases were
to the lungs 28 (75.7 %). Metastases also occurred to bones
7 (18.9 %), brain 4 (10.8 %), and liver 2 (5.4 %). DM were
observed, on average, 21 months (range 2–57) after sur-
gery. Among those patients that developed DM, 91.9 %
(34/37) demonstrated DM within 3 years of initial
treatment.
Table 3 shows the methods and clinical outcomes of
treatment in 37 patients with phyllodes tumor DM.
Between 1952 and 1985, six patients with lung metas-
tases were treated with hormone therapy (Testosterone),
monochemotherapy (Cyclophosphamide), and poly-
chemotherapy (Methotrexate ? Dactinomycin ? Cyclophos-
phamide ? Vincristine).
Between 1986 and 2010, 22 patients with lung metas-
tases were treated as follows:
– Ten patients with monochemotherapy: Ifosfamide (four
patients) or Doxorubicin (six patients)
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– Ten patients with polychemotherapy: Doxorubicin ?
Cisplatin (five patients), Doxorubicin ? Ifosfamide (three
patients), Doxorubicin ? Cyclophosphamide (two patients)
– Two patients: resection of metastases was combined
with Doxorubicin.
In 11 patients with bone or brain metastases, palliative
radiotherapy (PR) (20 Gy in five fractions) was used (two
patients with lung and bone metastases: PR was combined
with Doxorubicin ? Cyclophosphamide, five patients with
bone metastases only received PR ? Doxorubicin, one
patient with brain metastases received PR ? Doxorubicin,
and three patients with brain metastases received PR only).
The mean survival (MS) from the diagnosis of distant
metastases in the study patients was 7 months (2–17), and
the median 8 months. Among 24 patients with lung
metastases: complete remission (CR) occurred in three
patients (MS 9.1 months), partial remission (PR) in 10
patients (MS 8.2 months), and no remission (NR) in 11
patients (MS 4.3 months). The MS of patients with lung
and liver metastases was 7 months, and with lung and bone
metastases it was 9 months. In the group studied here, two
patients were treated with resection of individual lung
metastasis and Doxorubicin; they survived 8 and 9 months
after treatment. The longest MS was among patients with
bone metastases (11.8 months), and the worst MS was
among patients with brain metastases (2.8 months).
Table 3 shows the low efficacy of hormone therapy (MS
2 months) and monochemotherapy (Cyclophosphamide
MS 3 months, Ifosfamide 5 months). A longer MS was
obtained after the use of Doxorubicin monochemotherapy
(7 months), and Doxorubicin polychemotherapy with Cis-
platin, Cyclophosphamide, or Ifosfamide (9 months).
Discussion
For the study group of 295 patients with PT, 37 (12.5 %)
presented with DM, consistent with prior literature [1–3, 5,
6, 9, 11, 12, 14, 19–22]. Among 160 patients with benign
PT, 3 (1.9 %) developed DM, among 36 patients with
borderline PT, 6 (16.7 %) and among 99 patients with
malignant PT, 28 developed DM (28.3 %). The accepted
frequency of DM in benign, borderline, and malignant PT
is 0–2, 3–11, and 6–47 %, respectively [1–3, 5, 6, 9, 11–15,
22–24].
Most frequently, metastases are to the lung, bones,
brain, and liver; this is consistent with the patients reported
here [1, 2, 6, 11, 12]. DM from PT may also occur in other
organs, such as the heart, pleura, oral cavity, larynx, nasal
cavity, salivary glands, thyroid, adrenal glands, spleen,
pancreas, kidney, stomach, small and large intestine,
seminal glands, prostate, skin, ovary, and vulva to name
some [5, 8, 9, 11, 25].
The time span between treatment of the primary tumor
and possible manifestation of distant metastases varies
greatly, and ranges from 1 month to over 10 years; how-
ever, the majority of DM of PT are noted within the first
3 years [2, 6, 12, 14, 20, 26]. In this study group of
patients, DM were observed on average after 21 months (2-
57), in other reports: 15 months (Abdala and Sakr),
14 months (Barrio et al.), 21 months (Kapiris et al.),
30 months (Fou et al.), and 53 months (Asoglu et al.) [6,
14, 20, 24, 26].
The role of surgery for the treatment of disseminated PT
is limited to palliative management such as resection of
individual metastases [2]. An effective method of palliative
treatment may be irradiation of metastases, such as those to
the bones, brain, and mediastinal lymph nodes. Five of the
patients in this study, with bone metastases, had the longest
mean survival of all patients with DM of PT (11.8 months)
[2, 6, 19].
While the epithelial component of most PT contains
estrogen and progesterone receptors, hormone therapy did
not demonstrate any significant efficacy in the treatment of
DM [4, 6, 8, 11].
In the patients with DM from a PT, chemotherapy has
been considered the first-line treatment for many years [2,
9, 11, 15, 16, 25]. Many investigators have confirmed a low
efficacy of monochemotherapy (Cyclophosphamide, Ifos-
famide, Doxorubicin), although there are single reports of
spectacular, usually short-lasting, regressions [2, 15, 16,
18, 25, 27]. Slightly better regression, although usually
Table 1 Results of the treatment in 295 patients with PT
Phyllodes tumor No. of patients 5-year NED Distant Metastases
No of patients % No. of patients %
Benign 160 155 96.9 3a 1.9
Borderline 36 30 83.3 6 16.7
Malignant 99 71 71.7 28 28.3
Total 295 256 86.8 37a 12.5
a Two additional patients died without PT recurrences
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neither substantial nor long-lasting, is obtained after
treatment with polychemotherapy (Doxorubicin with Cis-
platin or Ifosfamide, Cisplatin with Etoposide [2, 15, 16,
18, 27]. Total regression of metastatic foci has been
reported as well [2, 16, 17, 28].
In this study group of patients with lung metastases, there
was a low efficacy of treatment with monochemotherapy
with Cyclophosphamide (MS 3 months) or Ifosfamide
(MS 5 months). There was a slightly better MS with
monochemotherapy using Doxorubicin (MS 7 months) and
Doxorubicin used in polychemotherapy with Cisplatin,
Cyclophosphamide, or Ifosfamide (MS months). The best
survival was observed in patients with bone metastases only
that were treated with palliative radiotherapy and Doxoru-
bicin (MS 11.8 months). No evident neurological
improvement was noted in the four patients with brain
metastases treated with palliative radiotherapy (MS
2.8 months).
Investigators differ in their assessment of survival in
patients with PT once manifestations of DM are noted.
Reinfuss et al. reported an MS of 4 months, Abdalla and
Sakr 5 months (1–11), Barth et al. 12 months, Kapiris et al.
16.6 months (1–24), and de Ross et al. 17 months (12–15)
[6, 12–14, 29]. It is generally reported that the survival
time of patients with DM from PT is shorter than
24 months, even though there are longer survival times,
even up to 16 years [2, 18]. In this group of patients, the
MS was 7 months (2–17) and the median was 8 months.
Phyllodes tumor DM carries a poor prognosis. In the
1950s and 1970s, chemotherapy was shown to have mini-
mal impact on survival of patients. However, data from the
literature and the results of this study with poly-
chemotherapy (Doxorubicin ? Ifosfamide or Cisplatin)
suggest that chemotherapy may be more efficient than
Table 2 Localization of DM in the group of 37 patients with PT
Localization No. of patients %
Lung 24 64.9
Lung ? bones 2 5.4
Lung ? liver 2 5.4
Bones 5 13.5
Brain 4 10.9
Total 37 100.0
Table 3 Methods and results of the treatment in 37 patients with phyllodes tumor DM
Localization of DM Treatment No. of
patients
Results
Remission Survival (months) from
diagnosis of DM
Lung (24 patients) Testosterone 1 NMa 2
Cyclophosphamide 2 NM 3 and 3
Methotrexate ? dactinomycin ?
Cyclophosphamide ? vincristine
3 NM 4, 4, and 4
Ifosfamide 4 PR—1 patient
NR—3 patients
6
6, 5, and 5
Doxorubicin 6 PR—4 patients
NR—2 patients
9, 9, 8, and 5
6 and 5
Resection of individual metastases ?
Doxorubicin
2 CR 8 and 9
Doxorubicin ? Cisplatin 3 PR—3 patients 9, 8, and 9
Doxorubicin ? Ifosfamide 3 CR—1 patients
PR—2 patients
11
10 and 9
Lung ? liver (2 patients) Doxorubicin ? Cisplatin 2 PR—1 patient
NR—1 patient
8
6
Lung ? bones (2 patients) Doxorubicin ? CyclophosphamideDoxorubicine ?
palliative radiotherapy
2 PR—1 patient
NR—1 patient
9
9
Bones (5 patients) Doxorubicin ? palliative radiotherapy 5 PR—5 patients 11, 11, 10, 10, and 17
Brain (4 patients) Palliative radiotherapy
Palliative radiotherapy ? Doxorubicin
3
1
NR
NR
2, 3, and 3
3
NR no remission
PR partial remission
CR complete remission
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previously thought [2, 7, 15, 16]. The NCCN recommends
that treatment of DM in patients with PT follow the algo-
rithm outlined in the NCCN Soft Tissue Sarcoma Clinical
Practice Guidelines in Oncology and novel drugs (Doc-
etaxel ? Gemcitabine, Pazopanib, or Trabectedin) may be
used for example [30]. Future studies to identify relevant
molecular targets should be carried out in order to define
more effective therapies for DM in patients with PT. In
2013, Jardim et al. described for the first time an NRAS
mutation with concomitant activation of P13 K/Akt/mTOR
with PT. The investigators reported markers for sensitivity
to taxane-based therapies, especially albumin-bound
paclitaxel [31].
Conclusion
In conclusion, on the basis of the results of this study and
data from the literature, the prognosis of patients with DM
from PT is poor, with an average survival of less than
2 years after diagnosis. The role of surgery and irradiation
in the treatment of these patients is very limited (resection
of individual DM, palliative irradiation DM in bones or
brain), and there is no role for hormone therapy. Our
findings of multidrug systemic therapy with Doxorubicin
and Ifosfamide suggest that chemotherapy may be more
efficient than once thought. At present, patients with DM
from PT of the breast should be treated in the same manner
as are patients with metastatic soft tissue sarcoma.
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